One of the most important things we can do to affect our health and promote longevity is to learn whether or not we have cancer. It is particularly important to screen for early forms of cancer so that we can eradicate them before they become a serious problem. Until now, it has not been possible or practical to screen for many common cancers. However, there is a new test available that enables us to screen for the presence of malignant cells in your body in such small numbers that upon their discovery it is easy to destroy them before they grow into a clinically significant cancer. As it turns out, every malignant cell in the body has on its surface certain protein markers that are not only specific to malignancy, but specific to the organ of origin. When the malignant cells reach a critical number of 2 million cells, enough of the protein is shed into the blood to allow us to detect its presence.
How The Test Works
The blood test identifies a specific type of protein in the blood, which exists only on the surface of a malignant cancer cell. Cell-surface, cancer-specific proteins are shed into the circulation and can be detected in the blood. These proteins serve as highly sensitive markers for early detection in both primary and recurrent cancer. The test is a valuable complement to early intervention. The blood test will detect a cancer of 2 million cells compared to 4.5 trillion cells for a positive mammogram.
The test uses techniques known as two-dimensional gel electrophoresis and western blot analysis along with a cell-surface, cancer-specific protein-antibody for detection. The result of the blood test is presented visually. Each type of cell-surface, cancer-specific protein has a particular location (molecular weight and isoelectric point) on the blot to demonstrate the proteins presence and to identify the tissue of origin.
Cancers revealed by the cell-surface, cancer-specific protein test:
- NON-SMALL CELL
- LUNG SMALL CELL
- MULTIPLE MYELOMA
- SQUAMOUS CELL
- TESTICULAR GERM CELL
Why Choose Regeneveda
Dr. Lobe is a world renowned cancer surgeon with over 35 years of experience. He has been an investigator on numerous NIH grants for cancer and served on Inter-group Cooperative Cancer Committees to design new protocols for decades. Many of his nearly 200 publications in peer-reviewed medical journals deal with his expertise in the management of a variety of cancers, their treatment, and results. Dr. Lobe spent over 20 years at St. Jude Children’s Research Hospital, much of that time as Chief of Pediatric Surgery, Dr. Lobe was intimately involved with the early work and progress of the clinical application of stem cell therapies. Dr. Lobe is as well versed in the conventional prevention, diagnosis, and management of cancer as he is with alternative adjunctive therapies for cancer. Having the ability to provide his patients with the best therapeutic, nutritional, and immune support available at all stages of dealing with cancer is one of his greatest passions.